{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:05:08Z","timestamp":1790949908006,"version":"4.1.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":126,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the present narrative review, we have summarized evidence on the pharmacological treatment of non-alcoholic fatty liver disease (NAFLD)\/metabolic dysfunction-associated steatotic liver disease (MASLD). We start by reviewing the epidemiology of the condition and its close association with obesity and type 2 diabetes. We then discuss how randomized\u2013controlled trials are performed following guidance from regulatory agencies, including differences and similarities between requirements of the US Food and Drug Administration and the European Medicine Agency. Difficulties and hurdles related to limitations of liver biopsy, a large number of screening failures in recruiting patients, as well as unpredictable response rates in the placebo group are evaluated. Finally, we recapitulate the strategies employed for potential drug treatments of this orphan condition. The first is to repurpose drugs that originally targeted T2DM and\/or obesity, such as pioglitazone, glucagon-like peptide 1 receptor agonists (liraglutide and semaglutide), multi-agonists (tirzepatide and retatrutide), and sodium-glucose transporter 2 inhibitors. The second is to develop drugs specifically targeting NAFLD\/MASLD. Among those, we focused on resmetirom, fibroblast growth factor 21 analogs, and lanifibranor, as they are currently in Phase 3 of their clinical trial development. While many failures have characterized the field of pharmacological treatment of NAFLD\/MASLD in the past, it is likely that approval of the first treatments is near. As occurs in many chronic conditions, combination therapy might lead to better outcomes. In the case of non-alcoholic steatohepatitis, we speculate that drugs treating underlying metabolic co-morbidities might play a bigger role in the earlier stages of disease, while liver-targeting molecules will become vital in patients with more advanced disease in terms of inflammation and fibrosis.<\/jats:p>","DOI":"10.1093\/gastro\/goae029","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T12:15:59Z","timestamp":1711023359000},"source":"Crossref","is-referenced-by-count":82,"title":["Advancements in pharmacological treatment of NAFLD\/MASLD: a focus on metabolic and liver-targeted interventions"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-3041","authenticated-orcid":false,"given":"Stefano","family":"Ciardullo","sequence":"first","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza , Monza, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Muraca","sequence":"additional","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza , Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Vergani","sequence":"additional","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza , Monza, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano Bicocca , Monza, Italy"},{"name":"European Reference Network on Hepatological Diseases (ERN RARE-LIVER) San Gerardo Hospital , Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Rehabilitation, Policlinico di Monza , Monza, Italy"},{"name":"Department of Medicine and Surgery, University of Milano Bicocca , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"2024042623580175100_goae029-B1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2024042623580175100_goae029-B3","doi-asserted-by":"crossref","first-page":"e065425","DOI":"10.1136\/bmjopen-2022-065425","article-title":"Trends in body mass index, overweight and obesity among adults in the USA, the NHANES from 2003 to 2018: a repeat cross-sectional survey","volume":"12","author":"Li","year":"2022","journal-title":"BMJ Open"},{"key":"2024042623580175100_goae029-B4","first-page":"347","article-title":"Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism","volume":"14","author":"Connor","year":"1938","journal-title":"Am J Pathol"},{"key":"2024042623580175100_goae029-B5","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.jhepr.2021.100261","article-title":"Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD\u2014Reconciling the present with the past","volume":"3","author":"Ayonrinde","year":"2021","journal-title":"JHEP Rep"},{"key":"2024042623580175100_goae029-B6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"2024042623580175100_goae029-B7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0040-1701443","article-title":"Drinking and obesity: alcoholic liver disease\/nonalcoholic fatty liver disease interactions","volume":"40","author":"\u00c5berg","year":"2020","journal-title":"Semin Liver Dis"},{"key":"2024042623580175100_goae029-B8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s11695-021-05885-x","article-title":"Prevalence of elevated liver stiffness among potential candidates for bariatric surgery in the United States","volume":"32","author":"Ciardullo","year":"2022","journal-title":"Obes Surg"},{"key":"2024042623580175100_goae029-B9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"2024042623580175100_goae029-B10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"2024042623580175100_goae029-B11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/HJH.0000000000002835","article-title":"Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population","volume":"39","author":"Ciardullo","year":"2021","journal-title":"J Hypertens"},{"key":"2024042623580175100_goae029-B12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/MEG.0000000000001191","article-title":"Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?","volume":"30","author":"Oikonomou","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B13","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"2024042623580175100_goae029-B14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am J Med"},{"key":"2024042623580175100_goae029-B15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2024042623580175100_goae029-B16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"2024042623580175100_goae029-B17","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"2024042623580175100_goae029-B20","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2024042623580175100_goae029-B22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int"},{"key":"2024042623580175100_goae029-B24","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep4.1969","article-title":"Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents","volume":"6","author":"Ciardullo","year":"2022","journal-title":"Hepatol Commun"},{"key":"2024042623580175100_goae029-B25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.21037\/hbsn-23-308","article-title":"Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition","volume":"12","author":"Ciardullo","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2024042623580175100_goae029-B26","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"key":"2024042623580175100_goae029-B27","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"2024042623580175100_goae029-B28","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int"},{"key":"2024042623580175100_goae029-B29","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"2024042623580175100_goae029-B30","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B32","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"Younossi","year":"2011","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B34","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"2024042623580175100_goae029-B36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B37","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"2024042623580175100_goae029-B38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jhep.2022.11.028","article-title":"NAFLD and NASH biomarker qualification in the LITMUS consortium\u2014lessons learned","volume":"78","author":"Rasmussen","year":"2023","journal-title":"J Hepatol"},{"key":"2024042623580175100_goae029-B40","doi-asserted-by":"crossref","first-page":"107352","DOI":"10.1016\/j.cct.2023.107352","article-title":"Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol","volume":"134","author":"Pavlides","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"2024042623580175100_goae029-B41","doi-asserted-by":"crossref","first-page":"108054","DOI":"10.1016\/j.diabres.2020.108054","article-title":"Treatment paradigm shifting implications of recent cardiovascular outcome trials: core insights on the brink of the 2020ies","volume":"161","author":"Standl","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"2024042623580175100_goae029-B42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003495-200060020-00009","article-title":"Pioglitazone","volume":"60","author":"Gillies","year":"2000","journal-title":"Drugs"},{"key":"2024042623580175100_goae029-B43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B44","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"2024042623580175100_goae029-B45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2024042623580175100_goae029-B46","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024042623580175100_goae029-B47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2024042623580175100_goae029-B48","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B49","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065: deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"2024042623580175100_goae029-B50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024042623580175100_goae029-B51","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2024042623580175100_goae029-B52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2024042623580175100_goae029-B53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0303-7207(98)00096-3","article-title":"Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression","volume":"141","author":"Dunphy","year":"1998","journal-title":"Mol Cell Endocrinol"},{"key":"2024042623580175100_goae029-B54","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.3390\/jcm12175597","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment","volume":"12","author":"Ciardullo","year":"2023","journal-title":"J Clin Med"},{"key":"2024042623580175100_goae029-B55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"2024042623580175100_goae029-B56","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"2024042623580175100_goae029-B57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"2024042623580175100_goae029-B58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024042623580175100_goae029-B59","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B60","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B61","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B62","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B63","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B65","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024042623580175100_goae029-B66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jama.2023.12718","article-title":"New weight loss drugs make headlines at diabetes meeting","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"key":"2024042623580175100_goae029-B68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"2024042623580175100_goae029-B69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2024042623580175100_goae029-B70","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/metabo14010040","article-title":"Endpoints in NASH clinical trials: are we blind in one eye?","volume":"14","author":"Lonardo","year":"2024","journal-title":"Metabolites"},{"key":"2024042623580175100_goae029-B73","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrendo.2014.143","article-title":"Thyroid hormone receptors and resistance to thyroid hormone disorders","volume":"10","author":"Ortiga-Carvalho","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"2024042623580175100_goae029-B74","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/apt.17747","article-title":"Editorial: Resmetirom\u2014a promising treatment option for NASH and liver fibrosis","volume":"59","author":"Targher","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2024042623580175100_goae029-B75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2024042623580175100_goae029-B76","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"2024042623580175100_goae029-B77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2024042623580175100_goae029-B78","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"2024042623580175100_goae029-B79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cen.12134","article-title":"Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status","volume":"80","author":"Lee","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024042623580175100_goae029-B82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B83","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"2024042623580175100_goae029-B84","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, Phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024042623580175100_goae029-B85"},{"key":"2024042623580175100_goae029-B86","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B87"},{"key":"2024042623580175100_goae029-B88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/hbsn-21-579","article-title":"Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease","volume":"11","author":"Yoneda","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2024042623580175100_goae029-B89","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042623580175100_goae029-B90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"key":"2024042623580175100_goae029-B91","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: Insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae029\/57341791\/goae029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae029\/57341791\/goae029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:49:40Z","timestamp":1731599380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goae029\/7658895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":91,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goae029","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,12,22]]},"article-number":"goae029"}}